Company Profile
Acumen Pharmaceuticals Stock Price, News & Analysis
- Ticker:
- ABOS
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
2.28 USD (+1.79%)
Close
Last updated: August 6, 2026
171M USD
Market cap
Why the stock is moving
The latest company update was “Acumen Pharmaceuticals to Report Second Quarter Financial Results on August 12, 2026”. ABOS changed 1.79% and closed at $2.28 on Aug 6, 2026, indicating a relatively limited closing-price reaction to this earnings update.
Company overview
Alzheimer’s Disease Antibody Company
Acumen Pharmaceuticals develops therapies targeting soluble amyloid-beta oligomers, which are believed to contribute directly to synaptic dysfunction in Alzheimer’s disease.
Sabirnetug
Sabirnetug is a monoclonal antibody designed to selectively bind toxic amyloid-beta oligomers while limiting interaction with monomers and plaques.
Enhanced Brain Delivery
Acumen is also developing an enhanced brain-delivery platform intended to improve central nervous system exposure of future biologics.
Future catalysts
Topline results from the Phase 2 ALTITUDE-AD study of sabirnetug are expected in late 2026.
An IND filing for the lead enhanced brain-delivery candidate is targeted for mid-2027.
Recent news
- 01
Acumen Pharmaceuticals to Report Second Quarter Financial Results on August 12, 2026
Source: Acumen Pharmaceuticals
- 02
- 03
- 04
- 05
Acumen Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Highlights
Source: Acumen Pharmaceuticals
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Acumen Pharmaceuticals (ABOS)?
Acumen Pharmaceuticals (ABOS) most recently closed at 2.28 USD, a +1.79% move versus the previous session.
What is the market cap of Acumen Pharmaceuticals (ABOS)?
Acumen Pharmaceuticals currently has a market capitalization of 171M USD on BioPharmSignal.
What does Acumen Pharmaceuticals do?
Alzheimer’s Disease Antibody Company Acumen Pharmaceuticals develops therapies targeting soluble amyloid-beta oligomers, which are believed to contribute directly to synaptic dysfunction in Alzheimer’s disease. Sabirnetug Sabirnetug is a monoclonal antibody designed to selectively bind toxic amyloid-beta oligomers while limiting interaction with monomers...
On which exchange is ABOS stock listed?
Acumen Pharmaceuticals (ABOS) is associated with NASDAQ, United States, Biopharma.
What is ALTITUDE-AD?
Topline results from the Phase 2 ALTITUDE-AD study of sabirnetug are expected in late 2026.
Which conditions is Acumen Pharmaceuticals targeting with ALTITUDE-AD?
Topline results from the Phase 2 ALTITUDE-AD study of sabirnetug are expected in late 2026.
How does Acumen Pharmaceuticals describe recent progress with ALTITUDE-AD?
Topline results from the Phase 2 ALTITUDE-AD study of sabirnetug are expected in late 2026.
What is Alzheimer?
Alzheimer’s Disease Antibody Company Acumen Pharmaceuticals develops therapies targeting soluble amyloid-beta oligomers, which are believed to contribute directly to synaptic dysfunction in Alzheimer’s disease.